AI in Healthcare

Despite a major setback in Angelman syndrome drug development, experts are optimistic about the role of AI in gene therapy. The recent clinical trial failure of an antisense oligonucleotide drug highlights challenges but also opens doors for precision medicine using machine learning. STAT reports that 40% of Angelman syndrome drugs in trials have failed, yet this isn’t a reason to abandon the approach. Instead, AI-enhanced design could dramatically improve outcomes and reduce development costs by up to 35%. This is especially critical as we look toward broader applications for neurological conditions. https://www.statnews.com/2026/09/04/angelman-syndrome-drug-ultragenyx-oak-hill-ionis/?utm_campaign=rss Source: https://www.statnews.com/2026/09/04/angelman-syndrome-drug-ultragenyx-oak-hill-ionis/?utm_campaign=rss View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request. MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy. Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member. Associate Broker. George Arnold Alexander III Director, ALEX Companies; Associate Broker, Alexander Tiffany Southwest, LLC. +1 713.918.9951 · [email protected]